- Y16
-
- $67.00
-
2026-08-04
- CAS:429653-73-6
- Purity: 99.85%
- Supply Ability: 10g
- Y16
-
-
2026-06-30
- CAS:429653-73-6
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 20Tons
|
| Product Name: | Y16 | | Synonyms: | Y16;4-[[3-[(3-Methylphenyl)methoxy]phenyl]methylene]-1-phenyl-3,5-pyrazolidinedione;Y16, >98%;Y16, 429653-73-6;3,5-Pyrazolidinedione, 4-[[3-[(3-methylphenyl)methoxy]phenyl]methylene]-1-phenyl-;Inhibitor,inhibit,Y-16,Y 16,Ras,Y16;4-(3-((3-Methylbenzyl)oxy)benzylidene)-1-phenylpyrazolidine-3,5-dione;Y16, 10 mM in DMSO | | CAS: | 429653-73-6 | | MF: | C24H20N2O3 | | MW: | 384.43 | | EINECS: | | | Product Categories: | | | Mol File: | 429653-73-6.mol |  |
| density | 1.273±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: soluble5mg/mL, clear (warmed) | | form | powder | | pka | 8.84±0.20(Predicted) | | color | , faint yellow to dark orange | | InChI | 1S/C24H20N2O3/c1-17-7-5-9-19(13-17)16-29-21-12-6-8-18(14-21)15-22-23(27)25-26(24(22)28)20-10-3-2-4-11-20/h2-15H,16H2,1H3,(H,25,27) | | InChIKey | ITMLWGWTDWJSRZ-UHFFFAOYSA-N | | SMILES | N2(NC(=O)C(=Cc3cc(ccc3)OCc4cc(ccc4)C)C2=O)c1ccccc1 |
| Hazard Codes | N | | Risk Statements | 50/53 | | Safety Statements | 60-61 | | RIDADR | UN 3077 9 / PGIII | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| Uses | Y16 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a Kd value of 76 nM. Y16 is active in blocking the interaction of LARG and related G-protein-coupled Rho GEFs with RhoA. Y16 shows no detectable effect on other diffuse B-cell lymphoma (Dbl) family Rho GEFs, Rho effectors, or a RhoGAP[1]. | | Biological Activity | Y16 is an inhibitor of G protein-coupled Rho GEFs. It blocks the binding of LARG and Rho with a Kd of 80 nM. | | in vitro | Y16 (10-30 μΜ; 24 hours; NIH 3T3 cells) could inhibit RhoA-GTP formation induced by serum dose dependently and is specific for RhoA.
Y16 (10-30 μΜ; 24 hours ; NIH 3T3 cells) efficiently inhibits serum or SDF-1α-induced phospho-MLC and phospho-FAK formation, which are downstream of RhoA. Cell Viability Assay | Cell Line: | NIH 3T3 cells | | Concentration: | 10 μΜ, 30 μΜ | | Incubation Time: | 24 hours | | Result: | Inhibited RhoA-GTP formation induced by serum dose dependently and was specific for RhoA. | Western Blot Analysis | Cell Line: | NIH 3T3 cells | | Concentration: | 10 μΜ, 30 μΜ | | Incubation Time: | 24 hours | | Result: | Inhibited serum or SDF-1α-induced phospho-MLC and phospho-FAK formation, which were downstream of RhoA. | | | target | | Target | Value | RhoGEFs
() | | References | [1] Shang X, et al. Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3155-60. DOI:10.1073/pnas.1212324110 |
| | Y16 Preparation Products And Raw materials |
|
|
Tag:Y16(429653-73-6)
Related Product Information
|
|
1,2,4,5-Benzenetetramine tetrahydrochloride
Y 11
TENOVIN-1
LY 303511 (hydrochloride)
PFK-015
CCT 137690
CTS-1027
TG101209
BIX 02189
BMS 833923
MS436
CNX-1351
Mutant IDH1 inhibitor
|
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
|